(TWST) Twist Bioscience - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US90184D1000

Synthetic Genes, Oligo Pools, NGS Tools, Antibody Libraries, Viral Controls

Stock: Biotechnology
Age 7.2y
MCap 2,529m
Avg Vol 1.22M (46.8M USD)
Beta 1.672
Volatility 69.66%

EPS (Earnings per Share)

EPS (Earnings per Share) of TWST over the last years for every Quarter: "2020-12": -0.72, "2021-03": -0.78, "2021-06": -0.78, "2021-09": -0.84, "2021-12": -0.91, "2022-03": -1.13, "2022-06": -1.08, "2022-09": -0.91, "2022-12": -0.74, "2023-03": -1.04, "2023-06": -0.78, "2023-09": -0.81, "2023-12": -0.75, "2024-03": -0.79, "2024-06": -1.47, "2024-09": -0.59, "2024-12": -0.53, "2025-03": -0.66, "2025-06": -0.47, "2025-09": -0.45, "2025-12": 0,
EPS CAGR: 41.88%
EPS Trend: 72.2%
Last SUE: 1.57
Qual. Beats: 1

Revenue

Revenue of TWST over the last years for every Quarter: 2020-12: 28.161, 2021-03: 31.204, 2021-06: 35.018, 2021-09: 37.951, 2021-12: 42.018, 2022-03: 48.127, 2022-06: 56.113, 2022-09: 57.306, 2022-12: 54.243, 2023-03: 60.18, 2023-06: 63.74, 2023-09: 66.946, 2023-12: 71.498, 2024-03: 75.302, 2024-06: 81.464, 2024-09: 84.71, 2024-12: 88.713, 2025-03: 92.793, 2025-06: 96.057, 2025-09: 99.009, 2025-12: null,
Rev. CAGR: 25.68%
Rev. Trend: 98.3%
Last SUE: 1.00
Qual. Beats: 1

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 69.7%
Value at Risk 5%th 108%
Relative Tail Risk -6.04%
Reward TTM
Sharpe Ratio -0.07
Alpha -40.27
CAGR/Max DD 0.22
Character TTM
Hurst Exponent 0.513
Beta 1.672
Beta Downside 1.125
Drawdowns 3y
Max DD 62.82%
Mean DD 30.67%
Median DD 31.13%

Description: TWST Twist Bioscience January 15, 2026

Twist Bioscience (NASDAQ:TWST) is a U.S.-based synthetic DNA manufacturer that produces custom gene fragments, oligo pools, and related reagents for a broad range of applications, including therapeutics, diagnostics, agricultural biotech, and emerging fields such as DNA data storage and computing.

Its product suite spans synthetic genes for drug discovery, next-generation sequencing (NGS) library kits (exome, custom panels, methylation detection), and specialty controls for viral diagnostics (e.g., SARS-CoV-2, monkeypox). The company also offers antibody-engineering solutions and a strategic partnership with bitBiome to expand its microbial-genomics capabilities.

Key quantitative signals (as of FY 2023) include revenue of roughly $400 million, a gross margin near 70 %, and a cash balance exceeding $300 million, which together provide runway for R&D and capacity expansion. The synthetic DNA market is projected to grow at a CAGR of 12-15 % through 2030, driven by accelerating demand for CRISPR-based therapies and large-scale NGS diagnostics-both of which are core end-markets for Twist.

For a deeper quantitative assessment, consult the ValueRay platform’s detailed TWST valuation model.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -77.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.12 > 0.02 and ΔFCF/TA -0.52 > 1.0
NWC/Revenue: 64.15% < 20% (prev 88.11%; Δ -23.97% < -1%)
CFO/TA -0.07 > 3% & CFO -47.6m > Net Income -77.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.64 > 1.5 & < 3
Outstanding Shares: last quarter (60.4m) vs 12m ago 4.15% < -2%
Gross Margin: 50.72% > 18% (prev 0.43%; Δ 5030 % > 0.5%)
Asset Turnover: 59.95% > 50% (prev 50.95%; Δ 9.01% > 0%)
Interest Coverage Ratio: -459.8 > 6 (EBITDA TTM -52.2m / Interest Expense TTM 167.0k)

Altman Z'' -13.26

A: 0.38 (Total Current Assets 333.0m - Total Current Liabilities 91.4m) / Total Assets 641.9m
B: -2.06 (Retained Earnings -1.32b / Total Assets 641.9m)
C: -0.12 (EBIT TTM -76.8m / Avg Total Assets 628.1m)
D: -7.82 (Book Value of Equity -1.32b / Total Liabilities 168.9m)
Altman-Z'' Score: -13.26= D

Beneish M -2.53

DSRI: 1.36 (Receivables 57.3m/34.9m, Revenue 376.6m/313.0m)
GMI: 0.84 (GM 50.72% / 42.61%)
AQI: 1.42 (AQ_t 0.24 / AQ_t-1 0.17)
SGI: 1.20 (Revenue 376.6m / 313.0m)
TATA: -0.05 (NI -77.7m - CFO -47.6m) / TA 641.9m)
Beneish M-Score: -2.53 = A

ValueRay F-Score (Strict, 0-100) 36.88

1. Piotroski: 2.50pt
2. FCF Yield: -3.19%
3. FCF Margin: -20.08%
4. Debt/Equity: 0.16
5. Debt/Ebitda: data missing
6. ROIC - WACC: -24.87%
7. RoE: -16.82%
8. Revenue Trend: 98.34%
9. EPS Trend: 72.20%

What is the price of TWST shares?

As of January 25, 2026, the stock is trading at USD 42.94 with a total of 1,126,010 shares traded.
Over the past week, the price has changed by +3.69%, over one month by +26.89%, over three months by +34.90% and over the past year by -19.44%.

Is TWST a buy, sell or hold?

Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.
  • Strong Buy: 6
  • Buy: 3
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the TWST price?

Issuer Target Up/Down from current
Wallstreet Target Price 39 -9.2%
Analysts Target Price 39 -9.2%
ValueRay Target Price 44.4 3.3%

TWST Fundamental Data Overview January 25, 2026

P/S = 6.7152
P/B = 5.1866
Revenue TTM = 376.6m USD
EBIT TTM = -76.8m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 75.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 75.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -107.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.37b USD (2.53b + Debt 75.6m - CCE 232.4m)
Interest Coverage Ratio = -459.8 (Ebit TTM -76.8m / Interest Expense TTM 167.0k)
EV/FCF = -31.36x (Enterprise Value 2.37b / FCF TTM -75.6m)
FCF Yield = -3.19% (FCF TTM -75.6m / Enterprise Value 2.37b)
FCF Margin = -20.08% (FCF TTM -75.6m / Revenue TTM 376.6m)
Net Margin = -20.63% (Net Income TTM -77.7m / Revenue TTM 376.6m)
Gross Margin = 50.72% ((Revenue TTM 376.6m - Cost of Revenue TTM 185.6m) / Revenue TTM)
Gross Margin QoQ = 51.35% (prev 53.40%)
Tobins Q-Ratio = 3.70 (Enterprise Value 2.37b / Total Assets 641.9m)
Interest Expense / Debt = 0.19% (Interest Expense 143.0k / Debt 75.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -60.7m (EBIT -76.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.64 (Total Current Assets 333.0m / Total Current Liabilities 91.4m)
Debt / Equity = 0.16 (Debt 75.6m / totalStockholderEquity, last quarter 473.0m)
Debt / EBITDA = 2.06 (negative EBITDA) (Net Debt -107.5m / EBITDA -52.2m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -107.5m / FCF TTM -75.6m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.37% (Net Income -77.7m / Total Assets 641.9m)
RoE = -16.82% (Net Income TTM -77.7m / Total Stockholder Equity 461.8m)
RoCE = -14.29% (EBIT -76.8m / Capital Employed (Equity 461.8m + L.T.Debt 75.6m))
RoIC = -13.14% (negative operating profit) (NOPAT -60.7m / Invested Capital 461.8m)
WACC = 11.73% (E(2.53b)/V(2.60b) * Re(12.08%) + D(75.6m)/V(2.60b) * Rd(0.19%) * (1-Tc(0.21)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.51%
Fair Price DCF = unknown (Cash Flow -75.6m)
EPS Correlation: 72.20 | EPS CAGR: 41.88% | SUE: 1.57 | # QB: 1
Revenue Correlation: 98.34 | Revenue CAGR: 25.68% | SUE: 1.00 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.47 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-2.47 | Chg30d=-0.710 | Revisions Net=+0 | Growth EPS=-16.8% | Growth Revenue=+14.3%
EPS next Year (2027-09-30): EPS=-2.05 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+17.0% | Growth Revenue=+15.1%

Additional Sources for TWST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle